MAP4343-d4

MAP4343-d4 is the deuterium labeled MAP4343. MAP4343 is the 3-methylether derivative of Pregnenolone. MAP4343 binds in vitro to microtubule-associated protein 2 (MAP2), stimulates the polymerization of tubulin, enhances the extension of neurites and protects neurons against neurotoxic agents[1][2][3].

Product Specifications

UNSPSC

12352211

Target

Isotope-Labeled Compounds; Microtubule/Tubulin

Type

Isotope-Labeled Compounds

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; Others

Applications

Cancer-programmed cell death

Field of Research

Neurological Disease

Solubility

10 mM in DMSO

Smiles

C[C@@]1([C@@]2([2H])C(C([2H])([2H])[2H])=O)[C@](CC2)([H])[C@@](CC=C(C3)[C@@]4(CC[C@@H]3OC)C)([H])[C@]4([H])CC1

Molecular Formula

C22H30D4O2

Molecular Weight

334.53

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Duchossoy Y, et, al. Treatment of experimental spinal cord injury with 3β-methoxy-pregnenolone. Brain Res. 2011 Jul 27;1403:57-66.|[3]Fontaine-Lenoir V, et, al. Microtubule-associated protein 2 (MAP2) is a neurosteroid receptor. Proc Natl Acad Sci U S A. 2006 Mar 21;103 (12) :4711-6.